Thermo Fisher Launches CorEvitas Vitiligo Registry

Thermo Fisher Scientific has launched the PPD CorEvitas Vitiligo Registry, a prospective, longitudinal observational registry designed to generate long-term real-world evidence on treatments for nonsegmental vitiligo (NSV) in adolescents and adults across the US. Announced on 29 July 2026 following an initial 14 July launch, the registry marks the newest addition to Thermo Fisher’s CorEvitas Clinical Registries portfolio in autoimmune and dermatology real-world evidence generation.

Vitiligo is a chronic, immune-mediated skin disorder characterised by loss of melanocytes resulting in depigmented patches. Treatment options have expanded significantly to include topical therapies, phototherapy, systemic corticosteroids and Janus kinase (JAK) inhibitors such as Incyte’s ruxolitinib cream (Opzelura), though important evidence gaps remain on long-term effectiveness, durability of response, treatment sequencing and patient-focused outcomes. The registry enrols adolescents aged 12 and older and adults with dermatologist-confirmed NSV, and follows them longitudinally in routine care settings. Data collection spans clinician-reported outcomes, patient-reported outcomes, treatment utilisation and patterns, disease burden and comorbidity data.

Dr Peter Wahl, VP and Global Head of Scientific Affairs for CorEvitas Clinical Registries, framed the registry as a mechanism to advance understanding of NSV in routine clinical practice and to capture the patient voice on how newly approved therapies affect day-to-day life. The launch extends Thermo Fisher’s real-world evidence infrastructure across autoimmune and dermatology disease areas, complementing existing CorEvitas registries. Real-world evidence platforms are increasingly critical to payer negotiations for high-cost specialty dermatology therapies and to post-approval regulatory commitments.

The commercial signal is Thermo Fisher extending its real-world evidence infrastructure into a rapidly commercialising dermatology segment. With JAK inhibitors and next-generation immunomodulators driving vitiligo pipeline activity at Incyte, Pfizer and AbbVie, registry data will underpin payer and prescriber decisions. Expect IQVIA, Icon and Syneos Health to sharpen their own dermatology real-world evidence offerings through the rest of 2026.

For the latest updates and in-depth insights into the world of Service Engineering, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!